Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: A multicentre audit and health economic analysis

British Journal of Dermatology

Volumn 152, Issue 3, 2005, Pages 444-450

  Chalmers, R J G ^a,b   Kirby, B ^a   Smith, A ^b   Burrows, P ^b   Little, R ^c   Horan, M ^d   Hextall, J M ^e   Smith, C H ^e   Klaber, M ^f   Rogers, S ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c KEELE UNIVERSITY   (United Kingdom)

^d City of Dublin Skin/Cancer Hospital   (Ireland)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f BROOMFIELD HOSPITAL   (United Kingdom)

Author keywords

Costs analysis; Hepatotoxicity; Liver biopsy; Methotrexate; Procollagen III aminopeptide; Psoriasis

Indexed keywords

METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BUDGET; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; DIAGNOSTIC VALUE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MEDICAL AUDIT; OUTCOMES RESEARCH; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RELIABILITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HEALTH CARE COSTS; HUMANS; LIVER DISEASES; MALE; MEDICAL AUDIT; METHOTREXATE; MIDDLE AGED; PATIENT SATISFACTION; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES; PROCOLLAGEN; PSORIASIS;

EID: 20244381405     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06422.x     Document Type: Article

References (25)

1. Boffa MJ, Chalmers RJG. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21:399-408.
2. Collins P, Rogers S. The efficacy of methotrexate in psoriasis - a review of 40 cases. Clin Exp Dermatol 1992; 17:257-60.
3. Saparito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004; 50:301-9.
4. Boffa MJ. Methotrexate for psoriasis - a postal survey of European dermatologists. J Eur Acad Dermatol Venereol 2003; 17 (Suppl. 3):136.
5. Roenigk HH Jr, Auerbach R, Maibach H et al. Methotrexate in psoriasis: Consensus Conference. J Am Acad Dermatol 1998; 38:478-85.
6. West SG. Methotrexate hepatotoxicity. Rheum Dis Clin 1997; 23:883-917.
7. Gawkrodger DJ. Current management of psoriasis. J Dermatol Treat 1997; 8:27-55.
8. Gilmore IT, Burroughs A, Murray-Lyon IM et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36:437-41.
9. Garcia-Tsao G, Boyer JL. Out-patient liver biopsy. How safe is it? Ann Intern Med 1998; 118:150-3.
10. van Theil DH, Gavaler JS, Wright H, Tzakis A. Liver biopsy: its safety and complications as seen at a liver transplant center. Transplantation 1993; 55:1087-90.
11. Boffa MJ, Chalmers RJG, Haboubi NY et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133:774-8.
12. Aithal GP, Haugk B, Gumustop B et al. Monitoring methotrexate induced hepatic fibrosis in patients with psoriasis: are serial biopsies justified? Aliment Pharmacol Ther 2004; 19:391-9.
13. Boffa MJ, Smith A, Chalmers RJG et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135:538-44.
14. Zachariac H, Heickendorff L, Segaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 144:100-3.
15. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 2000; 42:531-4.
16. Maurice PDL, Maddox AJ, Green CA et al. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005; 152:450-7.
17. Dahl MGC, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients wilh psoriasis. Br Med J 1971; i:625-30.
18. Podurgiel BJ, McGill DB, Ludwig J et al. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973; 48:787-92.
19. Millward-Sadler GH, Ryan TJ. Methotrexate-induced liver disease in psoriasis. Br J Dermatol 1974; 90:661-7.
20. Malatjalian DA, Ross JB, Williams CN et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia with analysis of risks from obesity, diabetes and alcohol consumption during long-lerm follow up. Can J Gastroenterol 1996; 10:369-75.
21. Verschuur AC, van Everdingen JJ, Cohen EB, Chamuleau RA. Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a decision analysis. Int J Dermatol 1992; 31:404-9.
22. Rademaker M, Webb JA, Lowe DG et al. Magnetic resonance imaging as a screening procedure for methotrexate induced liver damage. Br J Dermatol 1987; 117:311-16.
23. McHenry PM, Bingham EA, Callender ME et al. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. Br J Dermatol 1992; 127:122-5.
24. Zachariae H, Aslam HM, Bjerring P et al. Serum aminoterminal propeptide of type III collagen in psoriasis and psoriatic arthritis: relation to fibrosis and arthritis. J Am Acad Dermatol 1991; 25:50-3.
25. Kirby B, Fortune DG, Bhushan M et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000; 142:728-32.